IOWH-032
(Synonyms: 3-(3,5-二溴-4-羟基苯基)-N-(4-苯氧基苄基)-1,2,4-恶二唑-5-甲酰胺) 目录号 : GC11229
A modulator of CFTR
Cas No.:1191252-49-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Target: CFTR
IC50: 1.01 μM
IOWH-032 is a potent and synthetic extracellular cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor with IC50 value of 1.01 μM in T84 and CHO-CFTR cell based assays [1]. The CFTR chloride channel is the most attractive because it is the primary driver of secretion in cases of diarrhea caused by enterotoxigenic bacteria. CFTR plays an important role in transepithelial fluid homeostasis through controlling the flow of chloride ions and thus the movement of water in and out of cells [1].
In vitro: IOWH032 inhibited CFTR activity with IC50 value of 6.87 μM in T84-CFTR cell based assays [1]. IOWH-032 rapidly blocked and potentiated hCFTR activity in a concentration-dependent manner with apparent Kd value of 6.1 nM and 0.64 nM, respectively. However, IOWH-032 did not potentiate and only blocked mCFTR with an apparent Kd value of 42.9 μM [2].
In vivo: IOWH032 significantly inhibited cholera toxin (CTX)-induced secretion in a mouse closed-loop model. Moreover, IOWH032 (5 mg/kg, po dose) decreased the fecal output index by apparent 70% compared to vehicle (cholera toxin) in a cecetomized rat model. IOWH032 inhibited CFTR activity with IC50 value of 6.87 μM in T84-CFTR cell based assays [1].
References:
1. Doyle K, et al. Inhibitors Of The CFTR Chloride Ion Channel As Potential Treatment For Acute Secretory Diarrhea: Development Of 5-membered Heterocycles Suitable For Pre-clinical Evaluation.
1. de Hostos EL, Choy RK, Nguyen T. Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011;3(10):1317-25.
2. Cui G, Khazanov N, Stauffer B, Infield DT, Imhoff BR, Senderowitz H, et al. Potentiators exert distinct effects on human, murine, and Xenopus CFTR. Am J Physiol Lung Cell Mol Physiol. 2016:ajplung 00056 2016.
| Cas No. | 1191252-49-9 | SDF | |
| 别名 | 3-(3,5-二溴-4-羟基苯基)-N-(4-苯氧基苄基)-1,2,4-恶二唑-5-甲酰胺 | ||
| 化学名 | 3-(3,5-dibromo-4-oxocyclohexa-2,5-dien-1-ylidene)-N-[(4-phenoxyphenyl)methyl]-1,2,4-oxadiazole-5-carboxamide | ||
| Canonical SMILES | C1=CC=C(C=C1)OC2=CC=C(C=C2)CNC(=O)C3=NC(=C4C=C(C(=O)C(=C4)Br)Br)NO3 | ||
| 分子式 | C22H15Br2N3O4 | 分子量 | 545.18 |
| 溶解度 | ≥ 21.85mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8343 mL | 9.1713 mL | 18.3426 mL |
| 5 mM | 0.3669 mL | 1.8343 mL | 3.6685 mL |
| 10 mM | 0.1834 mL | 0.9171 mL | 1.8343 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。